Acute Migraine Therapeutics
1. Axert patent expiration
Treatment: Treatment of migraine
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5565447 (Pediatric) | JANSSEN PHARMS | Indole derivatives |
Nov, 2015
(10 years ago) | |
| US5565447 | JANSSEN PHARMS | Indole derivatives |
May, 2015
(10 years ago) | |
Drugs and Companies using ALMOTRIPTAN MALATE ingredient
Market Authorisation Date: 07 May, 2001
Dosage: TABLET
How can I launch a generic of AXERT before it's drug patent expiration?
More Information on Dosage
AXERT family patents
2. Frova patent expiration
Treatment: Acute treatment of migraine attacks with or without aura in adults
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5464864 | ENDO OPERATIONS | Use of tetrahydrocarbazone derivatives as 5HT1 receptor agonists |
Nov, 2015
(10 years ago) | |
| US5616603 | ENDO OPERATIONS | Enantiomers of carbazole derivatives as 5-HT1 -like agonists |
Apr, 2014
(11 years ago) | |
| US5637611 | ENDO OPERATIONS | Medicaments |
Jun, 2014
(11 years ago) | |
| US5827871 | ENDO OPERATIONS | Medicaments 1,2,3,4-tetrahydrocarbazoles and 5-HT1 agonist use thereof |
Oct, 2015
(10 years ago) | |
| US5962501 | ENDO OPERATIONS | Enantiomer of carbazole derivative as 5-HT1-like agonists |
Dec, 2013
(12 years ago) | |
Drugs and Companies using FROVATRIPTAN SUCCINATE ingredient
Market Authorisation Date: 08 November, 2001
Dosage: TABLET
How can I launch a generic of FROVA before it's drug patent expiration?
More Information on Dosage
FROVA family patents
3. Nurtec Odt patent
expiration
Treatment: Preventive treatment of episodic migraine in adults
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8314117 | PFIZER | CGRP receptor antagonists |
Feb, 2034
(8 years from now) | |
| US8759372 | PFIZER | N-(5S,6S,9R)-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-ctclohepta[b]Pyridin-9-yl-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-carboxylate salt |
Feb, 2033
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11083724 | PFIZER | Rimegepant for CGRP related disorders |
Mar, 2039
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-865) | May 27, 2024 |
| New Chemical Entity Exclusivity(NCE) | Feb 27, 2025 |
Drugs and Companies using RIMEGEPANT SULFATE ingredient
NCE-1 date: 28 February, 2024
Market Authorisation Date: 27 February, 2020
Dosage: TABLET, ORALLY DISINTEGRATING
More Information on Dosage
NURTEC ODT family patents
4. Relpax patent expiration
Treatment: Treatment of migraine with or without aura
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5545644 | UPJOHN | Indole derivatives |
Dec, 2016
(9 years ago) | |
| US6110940 | UPJOHN | Salts of an anti-migraine indole derivative |
Aug, 2017
(8 years ago) | |
Drugs and Companies using ELETRIPTAN HYDROBROMIDE ingredient
Market Authorisation Date: 26 December, 2002
Dosage: TABLET
How can I launch a generic of RELPAX before it's drug patent expiration?
More Information on Dosage
RELPAX family patents
5. Reyvow patent expiration
Treatment: Acute treatment of migraine; Acute treatment of migraine with or without aura in adults
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7423050 | ELI LILLY AND CO | Pyridinoylpiperidines as 5-HT1F agonists |
Feb, 2028
(2 years from now) | |
| US11053214 | ELI LILLY AND CO | Compositions and methods related to pyridinoylpiperidine 5-HT1F agonists |
Dec, 2037
(11 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8748459 | ELI LILLY AND CO | Pyridinoylpiperidines as 5-HT1F agonists |
Mar, 2023
(2 years ago) | |
| US12257246 | ELI LILLY AND CO | Composition of 2,4,6-trifluoro-n-[6-(1-methyl-piperidin-4-carbonyl)-pyridin-2-yl[-benzamide |
Jul, 2030
(4 years from now) | |
| US12071423 | ELI LILLY AND CO | Processes and intermediate for the large-scale preparation of 2,4,6-trifluoro-N-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide hemisuccinate, and preparation of 2,4,6-trifluoro-N-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide acetate |
Jul, 2040
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 31, 2025 |
Drugs and Companies using LASMIDITAN SUCCINATE ingredient
NCE-1 date: 01 February, 2024
Market Authorisation Date: 31 January, 2020
Dosage: TABLET
More Information on Dosage
REYVOW family patents
6. Ubrelvy patent expiration
Treatment: Acute treatment of migraine with or without aura in a patient with severe hepatic impairment; Acute treatment of migraine with or without aura in adults; Acute treatment of migraine with or without au...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9499545 | ABBVIE | Piperidinone carboxamide azaindane CGRP receptor antagonists |
Nov, 2031
(5 years from now) | |
| US8754096 | ABBVIE | Piperidinone carboxamide azaindane CGRP receptor antagonists |
Jul, 2032
(6 years from now) | |
| US8912210 | ABBVIE | Piperidinone carboxamide azaindane CGRP receptor antagonists |
Dec, 2033
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11717515 | ABBVIE | Treatment of migraine |
Dec, 2041
(15 years from now) | |
| US9833448 | ABBVIE | Piperidinone carboxamide azaindane CGRP receptor antagonists |
Nov, 2031
(5 years from now) | |
| US12329750 | ABBVIE | NA |
Dec, 2041
(15 years from now) | |
| US12194030 | ABBVIE | Treatment of migraine |
Dec, 2041
(15 years from now) | |
| US12220408 | ABBVIE | Treatment of migraine |
Jan, 2035
(9 years from now) | |
| US12070450 | ABBVIE | Treatment of migraine |
Dec, 2041
(15 years from now) | |
| US11857542 | ABBVIE | Treatment of migraine |
Dec, 2041
(15 years from now) | |
| US12458632 | ABBVIE | NA |
Jan, 2035
(9 years from now) | |
| US12168004 | ABBVIE | Treatment of migraine |
Jan, 2035
(9 years from now) | |
| US11925709 | ABBVIE | Tablet formulation for CGRP active compounds |
Jan, 2035
(9 years from now) | |
| US12458633 | ABBVIE | NA |
Jan, 2035
(9 years from now) | |
| US10117836 | ABBVIE | Tablet formulation for CGRP active compounds |
Jan, 2035
(9 years from now) | |
| US12310953 | ABBVIE | Pharmaceutical formulations for the treatment of migraine |
Jan, 2035
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 23, 2024 |
Drugs and Companies using UBROGEPANT ingredient
NCE-1 date: 24 December, 2023
Market Authorisation Date: 23 December, 2019
Dosage: TABLET
More Information on Dosage
UBRELVY family patents
7. Zavzpret patent expiration
Treatment: Administration of zavegepant for acute treatment of migraine with or without aura
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8481546 | PFIZER | CGRP receptor antagonist |
Oct, 2031
(5 years from now) | |
| US7220862 | PFIZER | Calcitonin gene related peptide receptor antagonists |
Jan, 2024
(1 year, 11 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7314883 | PFIZER | Anti-migraine treatments |
Dec, 2023
(2 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 09, 2028 |
Drugs and Companies using ZAVEGEPANT HYDROCHLORIDE ingredient
NCE-1 date: 10 March, 2027
Market Authorisation Date: 09 March, 2023
Dosage: SPRAY, METERED
More Information on Dosage
ZAVZPRET family patents